VYNE Therapeutics Inc.

VYNE

US92941V3087

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
2.76 ^USD	-4.50%		+1.47%	+18.45%

May. 09	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	MT
May. 09	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

VYNE Therapeutics Inc. Appoints Patrick G. Lepore to its Board of Directors

September 14, 2020 at 08:00 am EDT

VYNE Therapeutics Inc. announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020. Mr. LePore has more than 40 years of experience in the pharmaceutical industry, in both private and public sectors, and with board and operational experience in each. He served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies Inc. from September 2006 to 2012.

Latest news about VYNE Therapeutics Inc.

Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	May. 09	MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	May. 06	MT
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	May. 06	CI
Transcript : VYNE Therapeutics Inc. - Special Call	Apr. 04
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	Feb. 29	MT
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	CI
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	Jan. 03	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	Nov. 13	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : VYNE Therapeutics Inc. - Special Call	Nov. 09
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors	Oct. 31	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30	MT
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	23-10-30	MT
Top Premarket Gainers	23-10-30	MT
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	23-10-30	CI
VYNE Therapeutics Inc. announced that it expects to receive $88.151509 million in funding	23-10-26	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000	23-08-14	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	23-05-12	MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $99,000	23-05-11	MT
VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions	23-05-01	CI

Chart VYNE Therapeutics Inc.

Duration

Period

More charts

Company Profile

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Society for Investigative Dermatology Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for VYNE Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.76 USD

Average target price

5.583 USD

Spread / Average Target

+102.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VYNE THERAPEUTICS INC.	+18.45%	40.75M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.60%	364B
MERCK & CO., INC.	+20.83%	326B
ABBVIE INC.	+5.69%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.77%	167B
PFIZER, INC.	+0.10%	161B

Other Pharmaceuticals